Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Toxin Management Of Upper Facial Rhytidosis And Blepharospasm.

S. Seiff, O. M. Zwick
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Botulinum toxin is a neuromuscular blocking agent produced by Clostridium botulinum that has been proven to be an effective agent in the treatment of facial dystonia and upper facial rhytidosis. Since the original description of the toxin by Alan Scott [1] for strabismus 3 decades ago, the clinical use of this medication has expanded in an exponential fashion. Although the cosmetic benefits of botulinum toxin have become widely known, the full potential of this agent is yet to be realized. Its applications have grown to include treatment of a variety of disorders spanning many subspecialties including gastroenterology, pain management, otolaryngology, ophthalmology, dermatology, and neurology. Botulinum toxin is considered as a potential treatment in any situation involving inappropriate or exaggerated muscle contraction. The Food and Drug Administration (FDA) approved the use of botulinum toxin (Botox; Allergan Pharmaceuticals, Inc, Irvine, CA) to treat blepharospasm and strabismus in 1989. In December 2000, approval was given to treat cervical dystonia, a neurologic movement disorder causing severe neck and shoulder contractions, in December 1989. In April 2002, the FDA announced the approval of botulinum toxin type A (Botox Cosmetic; Allergan) to improve temporarily the appearance of glabellar lines. The product’s manufacturer has marketed botulinum toxin type A for this new indication, and the use of this product has skyrocketed. This article discusses the development of the use of botulinum toxin and then focuses on its benefits in treating facial dystonia and upper facial rhytidosis.
This paper references
Cosmetic Botulinum Toxin Injections
Susan R. Carter (1997)
A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
J. A. Carruthers (2002)
The use of botulinum toxin in blepharospasm.
N. Shorr (1985)
Treatment of blepharospasm with botulinum toxin. A preliminary report.
B. Frueh (1984)
Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm
W. Jost (2001)
Hemifacial spasm due to intracranial tumor. An international survey of botulinum toxin investigators.
C. Sprik (1988)
Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.
G. Defazio (2002)
Development of botulinum toxin therapy.
A. B. Scott (2004)
Motor nerve sprouting in human orbicularis muscle after botulinum A injection.
J. Holds (1990)
Double‐blind, placebo‐controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis
P. Greene (1990)
Blepharospasm: Past, Present, and Future
R. Anderson (1998)
Crystalline Preparation of Botulinum Toxin Type a (Botox): Degradation in Potency with Storage
M. Gartlan (1993)
Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet.
N. Lowe (2002)
Botulinum A toxin injection as a treatment for blepharospasm.
A. Scott (1985)
Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study
M. Keen (1994)
Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
A. B. Scott (1980)
Aesthetic Indications for Botulinum Toxin Injection
B. Guyuron (1994)
Cosmetic dermatologic surgery.
S. Stegman (1982)
Comparison of Therapeutic Efficacies of Type A and F Botulinum Toxins for Blepharospasm
T. Mezaki (1995)
Botulinum antibodies in dystonic patients treated with type A botulinum toxin
M. Zuber (1993)
Efficacy of Reconstituted and Stored Botulinum Toxin Type A: An Electrophysiologic and Visual Study in the Auricular Muscle of the Rabbit
M. Jabor (2003)
The use of botulinum A toxin to ameliorate facial kinetic frown lines.
J. Foster (1996)
Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.
J. Dutton (1988)
Reconstituted Botulinum Toxin Type A Does Not Lose Potency in Humans If It Is Refrozen or Refrigerated for 2 Weeks Before Use
R. Sloop (1997)
Cosmetic Denervation of the Muscles of Facial Expression with Botulinum Toxin A Dose‐Response Study
A. García (1996)
Increased Patient Comfort Utilizing Botulinum Toxin Type A Reconstituted with Preserved Versus Nonpreserved Saline
D. M. Kwiat (2004)
Hemifacial spasm
R. Auger (1979)
Multicenter, Double‐Blind Study of the Efficacy of Injections With Botulinum Toxin Type A Reconstituted Up to Six Consecutive Weeks Before Application
D. Hexsel (2003)
Treatment of blepharospasm with botulinum toxin.
E. A. Tsoy (1985)
Serum antibody production to botulinum A toxin.
R. Siatkowski (1993)
Benign Essential Blepharospasm
J. McCann (2005)
Anesthesia with EMLA® Cream for Botulinum A Toxin Injection into Eyelids
M. Söylev (2002)
Treatment of facial spasm with botulinum toxin. An interim report.
B. Frueh (1986)
Etiology and definitive microsurgical treatment of hemifacial spasm. Operative techniques and results in 47 patients.
P. Jannetta (1977)
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm.
J. Jankovic (1990)
Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm
R. Çakmur (2002)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar